Eli Lilly (LLY) vs. Tesla (TSLA)
This page compares Eli Lilly (LLY) with Tesla (TSLA) using performance and risk, profitability, financial strength, growth, dividends, and valuation metrics.
Company Profile
Eli Lilly (LLY) is classified in the Health Care sector (Pharmaceuticals, Biotechnology & Life Sciences), whereas Tesla (TSLA) belongs to Consumer Discretionary (Automobiles & Components) — their GICS classifications point to very different parts of the market.
| Symbol | LLY | TSLA |
|---|---|---|
| Name | Eli Lilly and Company | Tesla, Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Consumer Discretionary |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Automobiles & Components |
| GICS Industry | Pharmaceuticals | Automobiles |
| GICS Sub-Industry | Pharmaceuticals | Automobile Manufacturers |
| Market Capitalization | 1,003.45 billion USD | 1,468.49 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | June 1, 1972 | June 29, 2010 |
| Security Type | Common Stock | Common Stock |
Valuation
Price-to-Earnings Ratio (TTM)
Eli Lilly (LLY) at 40.00 hovers around the typical industry Price-to-Earnings Ratio (TTM), while Tesla (TSLA) at 358.72 sits above its industry benchmark range — an elevated trailing earnings multiple for TSLA relative to peers.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
40.00
- Max
- 76.34
- Q3
- 42.08
- Median
- 25.10
- Q1
- 14.48
- Min
- 1.55
TSLA
Automobiles & Components industry group
358.72
- Max
- 49.66
- Q3
- 33.42
- Median
- 20.07
- Q1
- 13.51
- Min
- 7.10
Price-to-Sales Ratio (TTM)
Eli Lilly (LLY) at 13.89 prices around its industry’s typical Price-to-Sales Ratio (TTM), while Tesla (TSLA) at 15.00 clears its benchmark range — TSLA looks notably rich on sales.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.89
- Max
- 51.32
- Q3
- 22.55
- Median
- 6.57
- Q1
- 3.36
- Min
- 0.01
TSLA
Automobiles & Components industry group
15.00
- Max
- 3.00
- Q3
- 1.54
- Median
- 0.57
- Q1
- 0.31
- Min
- 0.00
Price-to-Book Ratio (MRQ)
Measured against book value, both Eli Lilly (LLY) at 32.23 and Tesla (TSLA) at 17.86 look expensive — each Price-to-Book Ratio (MRQ) sits above its industry’s benchmark range.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
32.23
- Max
- 12.58
- Q3
- 6.24
- Median
- 3.34
- Q1
- 1.64
- Min
- -3.91
TSLA
Automobiles & Components industry group
17.86
- Max
- 4.39
- Q3
- 2.37
- Median
- 1.52
- Q1
- 0.84
- Min
- -0.59
Valuation at a Glance
| Symbol | LLY | TSLA |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 40.00 | 358.72 |
| Price-to-Sales Ratio (TTM) | 13.89 | 15.00 |
| Price-to-Book Ratio (MRQ) | 32.23 | 17.86 |
| Free Cash Flow Yield | 0.91% | 0.36% |
Profitability
Return on Equity (TTM)
Eli Lilly (LLY) posts Return on Equity (TTM) of 107.46%, above its industry benchmark range, while Tesla (TSLA) at 4.90% sits closer to the industry mid-range.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
107.46%
- Max
- 99.40%
- Q3
- 2.92%
- Median
- -31.42%
- Q1
- -61.80%
- Min
- -158.89%
TSLA
Automobiles & Components industry group
4.90%
- Max
- 41.97%
- Q3
- 11.32%
- Median
- 5.13%
- Q1
- -14.13%
- Min
- -49.98%
Net Profit Margin (TTM)
Eli Lilly (LLY) at 34.99% converts revenue to bottom-line profit above its industry’s benchmark range, while Tesla (TSLA) at 3.95% keeps roughly the typical share for its industry.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
34.99%
- Max
- 13.59%
- Q3
- 4.00%
- Median
- 0.00%
- Q1
- -2.47%
- Min
- -11.53%
TSLA
Automobiles & Components industry group
3.95%
- Max
- 15.12%
- Q3
- 4.34%
- Median
- 1.53%
- Q1
- -3.18%
- Min
- -13.87%
Operating Profit Margin (TTM)
Eli Lilly (LLY) at 49.39% operates in the top Operating Profit Margin (TTM) quartile, ahead of Tesla (TSLA) at 4.20%, which runs around its industry’s norm.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
49.39%
- Max
- 100.30%
- Q3
- 4.49%
- Median
- 0.00%
- Q1
- -127.25%
- Min
- -313.85%
TSLA
Automobiles & Components industry group
4.20%
- Max
- 18.83%
- Q3
- 8.71%
- Median
- 3.75%
- Q1
- -1.25%
- Min
- -14.77%
Profitability at a Glance
| Symbol | LLY | TSLA |
|---|---|---|
| Return on Equity (TTM) | 107.46% | 4.90% |
| Return on Assets (TTM) | 20.74% | 2.23% |
| Net Profit Margin (TTM) | 34.99% | 3.95% |
| Operating Profit Margin (TTM) | 49.39% | 4.20% |
| Gross Profit Margin (TTM) | 82.83% | 19.07% |
Growth
Revenue Growth
Revenue Growth at a Glance
| Symbol | LLY | TSLA |
|---|---|---|
| 1-Year Revenue Growth | 44.70% | -2.93% |
| 3-Year Revenue CAGR | 31.69% | 5.19% |
EPS Growth
EPS Growth at a Glance
| Symbol | LLY | TSLA |
|---|---|---|
| 1-Year EPS Growth | 95.99% | -47.06% |
| 3-Year EPS CAGR | 51.71% | -33.18% |
Financial Strength
Current Ratio (MRQ)
Tesla (TSLA) at 2.04 keeps Current Ratio (MRQ) within its industry mid-range, while Eli Lilly (LLY) at 1.50 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for LLY.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.50
- Max
- 24.81
- Q3
- 11.82
- Median
- 5.63
- Q1
- 2.69
- Min
- 0.23
TSLA
Automobiles & Components industry group
2.04
- Max
- 4.97
- Q3
- 2.69
- Median
- 1.85
- Q1
- 1.14
- Min
- 0.38
Debt-to-Equity Ratio (MRQ)
Tesla (TSLA) at 0.19 maintains Debt-to-Equity Ratio (MRQ) in the lower-leverage quartile, while Eli Lilly (LLY) at 1.39 sits in the higher-leverage quartile.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.39
- Max
- 1.60
- Q3
- 0.68
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
TSLA
Automobiles & Components industry group
0.19
- Max
- 2.53
- Q3
- 1.19
- Median
- 0.72
- Q1
- 0.26
- Min
- 0.00
Financial Strength at a Glance
| Symbol | LLY | TSLA |
|---|---|---|
| Current Ratio (MRQ) | 1.50 | 2.04 |
| Debt-to-Equity Ratio (MRQ) | 1.39 | 0.19 |
| Net Debt / EBITDA | 1.05 | -2.60 |
Dividends
Dividend Yield (TTM)
Tesla (TSLA) pays no dividend (yield 0.00%) — often a deliberate choice to reinvest earnings rather than return cash. Meanwhile Eli Lilly (LLY) reports a yield of 0.61%, ranking against industry peers normally.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.61%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TSLA
Automobiles & Components industry group
0.00%
- Max
- 5.05%
- Q3
- 2.12%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Tesla (TSLA) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a payout of 22.13%, ranking against industry peers normally.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.13%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TSLA
Automobiles & Components industry group
0.00%
- Max
- 84.24%
- Q3
- 33.71%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividends at a Glance
| Symbol | LLY | TSLA |
|---|---|---|
| Dividend Yield (TTM) | 0.61% | 0.00% |
| Dividend Payout Ratio (TTM) | 22.13% | 0.00% |
Performance & Risk
Tesla (TSLA) has an aggressive beta of 1.82, indicating higher sensitivity to broad-market moves, while Eli Lilly (LLY) is defensive at 0.52 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.
Performance & Risk at a Glance
| Symbol | LLY | TSLA |
|---|---|---|
| 1-Year Return | 47.97% | 37.34% |
| 1-Year Volatility | 38.14% | 44.52% |
| Beta | 0.52 | 1.82 |
| 3-Month Avg. Volume | 3.10M | 59.54M |